Pediatric Cutaneous Graft‐Versus‐Host Disease: Clinical Presentations, Management, and Emerging Therapies

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Clinical review highlights therapeutic options and drug response in pediatric patients with cutaneous GVHD, indicating needs for improved safety.

Management of cutaneous graft‐versus‐host disease requires a comprehensive approach, emphasizing multidisciplinary care for pediatric patients with long‐term morbidity.
Recent advances in therapeutic options include newly FDA‐approved treatments for steroid‐refractory disease, improving drug response in treatment.
Observational analysis focusing on pediatric patients with cutaneous GVHD demonstrates the necessity of clinical classification systems for better management.
Addressing age‐specific presentation and potential of immunosuppressive therapies may require further research for enhanced safety and efficacy in treatment.

Jennifer T. Huang (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Clinical review highlights therapeutic options and drug response in pediatric patients with cutaneous GVHD, indicating needs for improved safety.